Evidence map›Paper›PMID 39281194›Full record

ArticleIJID regions2024

SARS-CoV-2 seroprevalence in people living with HIV in South Sudan.

Helen M Chun, Dennis K Lodiongo, Kyle Milligan, Grace J Lesuk, Divya Patel, Ray W Shiraishi, Diana Martin, Ashley K Simon, Emilio Dirlikov, Hetal K Patel and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJID regions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Helen M ChunDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Atlanta, USA.
Dennis K LodiongoDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Juba, South Sudan.
Kyle MilliganDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Atlanta, USA.
Grace J LesukICAP at Columbia University, Juba, South Sudan.
Divya PatelDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Atlanta, USA.
Ray W ShiraishiDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Atlanta, USA.
Diana MartinDivision of Parasitic Diseases and Malaria, Global Health Center, Centers for Disease Control and Prevention, Atlanta, USA.
Ashley K SimonDivision of Parasitic Diseases and Malaria, Global Health Center, Centers for Disease Control and Prevention, Atlanta, USA.
Emilio DirlikovDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Maputo, Mozambique.
Hetal K PatelDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Atlanta, USA.
Dennis EllenbergerDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Atlanta, USA.
Habtamu A WorkuICAP at Columbia University, Juba, South Sudan.
Yen T DuongICAP at Columbia University, New York, USA.
Robert O EkongICAP at Columbia University, Juba, South Sudan.
Joel S KatoroDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Juba, South Sudan.
Shambel A HussenICAP at Columbia University, Juba, South Sudan.
Michael L LokorePublic Health Laboratory, Ministry of Health, Juba, South Sudan.
Gregory WaniPublic Health Laboratory, Ministry of Health, Juba, South Sudan.
Sudhir BungaDivision of Global HIV & Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Juba, South Sudan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The burden of SARS-CoV-2 infection in people living with HIV (PLHIV) in South Sudan is unknown. Methods: We conducted a cross-sectional seroprevalence survey of SARS-CoV-2 immunoglobulin (Ig) G antibodies and other diseases of public health importance (strongyloidiasis, toxoplasmosis) in PLHIV in South Sudan during April 1, 2020-April 30, 2022. We used a multiplex SARS-CoV-2 immunoassay to detect IgG antibodies targeting the SARS-CoV-2 spike, receptor binding domain, and nucelocapsid (N) proteins, and antigens for other pathogens ( Results: Among 3518 samples tested, seroprevalence of IgG antibodies to SARS-CoV-2 spike protein and receptor binding domain 591 and nucleocapsid ranged from 1.4% (95% confidence interval [CI]: 0.9-2.1%) in April-June 2020 to 53.3% (95% CI: 49.5-57.1%) in January-March 2022. The prevalence of Conclusions: By early 2022, PLHIV in South Sudan had high rates of SARS-CoV-2 seropositivity. Surveillance of diseases of global health concern in PLHIV is crucial to estimate population-level exposure and inform public health responses.

Indexed as

COVID-19People living with HIVSARS-CoV-2Seroprevalence

Identifiers

PMID39281194
PMCPMC11399597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.